Compugen (CGEN) Corporate presentation summary

Vision and strategy

• Aims to transform patient lives by developing first-in-class therapeutics using a proprietary computational discovery platform, Unigen™.

• Focuses on novel immuno-oncology antibodies with a rich pipeline and validating partnerships, including AstraZeneca and Gilead.

• Eligible for over $1 billion in milestones plus royalties from partnerships.

• Cash balance of $113.2M as of September 30, 2024, with expected runway into 2027.

Pipeline and clinical programs

• Lead assets include COM701 (anti-PVRIG) and COM902 (anti-TIGIT), both with potential best/first-in-class profiles.

• COM701 advancing into an adaptive platform trial for relapsed platinum-sensitive ovarian cancer, with study initiation in Q2 2025 and interim analysis projected for H2 2026.

• COM503 (anti-IL-18BP) licensed to Gilead, with up to $848M deal value and Phase 1 initiation planned for Q4 2024.

• Multiple assets in preclinical and research stages, including undisclosed programs.

Clinical data and efficacy

• COM701 demonstrates clinical benefit in tumors typically unresponsive to immunotherapy, including platinum-resistant ovarian cancer, MSS colorectal, endometrial, and breast cancers.

• Triplet combinations (COM701 + anti-PD-1 + anti-TIGIT) show consistent efficacy and safety, with ORR up to 20% and DCR up to 46% in heavily pretreated ovarian cancer.

• Durable and deep responses observed, including complete and partial responses lasting over a year.

• COM902 monotherapy showed a 50% disease control rate in early studies.